Companies · Biotechnology
Framingham · Biotechnology
Diligence memoA one-page analyst read on Bio-Tree Systems, Inc. — recommendation, valuation, rhythm, risks.→Bio-Tree Systems, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Bio-Tree Systems, Inc. is one of 4293 Biotechnology companies tracked from Framingham. By capital raised it ranks in the long tail (ahead of 17% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.
Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seed — a round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 17% of sector peers (real $). Modeled value above 46% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #4 of 62.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Cellay, Inc. | Pre-Seed | $1.0M | $55.2M | 2.00× |
| Cellutions Inc | Pre-Seed | $1.0M | $55.2M | 2.00× |
| Atherotech, Inc. | Pre-Seed | $999K | $55.2M | 2.00× |
| Bio-Tree Systems, Inc. this company | Pre-Seed | $950K | $52.4M | 1.90× |
| Theocorp Holding Company, LLC | Pre-Seed | $900K | $49.7M | 1.80× |
| Invoy Technologies, L.L.C. | Pre-Seed | $898K | $49.6M | 1.80× |
| Amnis Corp | Pre-Seed | $894K | $49.3M | 1.79× |
| Visen Medical Inc | Pre-Seed | $885K | $48.9M | 1.77× |
| Orthera, Inc. | Pre-Seed | $1.6M | $47.8M | 1.73× |
| Kika Medical International Co | Pre-Seed | $1.3M | $46.9M | 1.70× |
| Octamer Inc | Pre-Seed | $821K | $45.3M | 1.64× |
| Dynatherm Medical Inc | Pre-Seed | $818K | $45.2M | 1.64× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Pre-Seed | $950K | 2009-06-04 | $5.3M | $52.4M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Bernard Gordon | — | 3 other | 2009-06 |
| Edwin L. Miller | — | 1 other | 2009-06 |
| Ethan Rasiel | — | 1 other | 2009-06 |
| Kenneth I. Kaitin | — | 1 other | 2009-06 |
| Joseph Mundy | — | — | 2009-06 |
| Raul A. Brauner | — | — | 2009-06 |
Bio-Tree Systems, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Curis Inc | Biotechnology | Pre-Seed | $964K | $53.2M | network1 shared operator · same sector · same stage |
| NanoTomer, Inc. | Biotechnology | Pre-Seed | $950K | $52.4M | same sector · same stage |
| ALRGN Bio, Inc. | Biotechnology | Pre-Seed | $946K | $52.2M | same sector · same stage |
| EternoGen Aesthetics, LLC | Biotechnology | Pre-Seed | $939K | $46.3M | same sector · same stage |
| Cyto Wave Technologies Inc. | Biotechnology | Pre-Seed | $965K | $53.3M | same sector · same stage |
| LightStat, LLC | Biotechnology | Pre-Seed | $970K | $53.6M | same sector · same stage |
| Real Imaging, Ltd. | Biotechnology | Pre-Seed | $930K | $51.3M | same sector · same stage |
| One World Lab, Inc. | Biotechnology | Pre-Seed | $981K | $54.2M | same sector · same stage |
See where Bio-Tree Systems, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Bio-Tree Systems, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.